Skip to content

Loeb Represents Mountain Crest Acquisition Corp. II in Better Therapeutics Merger

Loeb & Loeb LLP advised Mountain Crest Acquisition Corp. II., a special purpose acquisition company, in connection in its merger with Better Therapeutics, a prescription digital therapeutics company. The company will be known as “Better Therapeutics” and will list on the NASDAQ under symbol “BTTX.” It is currently valued at $187 million.

The Loeb & Loeb deal team representing Mountain Crest in this transaction include partners Tahra Wright, Ronelle C. Porter, Andrei Sirabionian, Jim CzabanMarina Casani, and William J. Voller III.